Methylation of tumor suppressor genes in a novel panel predicts clinical outcome in paraffin-embedded bladder tumors
- 28 February 2014
- journal article
- research article
- Published by Springer Nature in Tumor Biology
- Vol. 35 (6) , 5777-5786
Abstract
DNA methylation of tumor suppressor genes (TSGs) represents a frequent and early epigenetic event with potential applications for cancer detection and disease evolution. Our aim was to examine the stratification and prognostic biomarker role of the methylation of a novel panel of TSGs in bladder cancer. The methylation status of 18 TSGs was evaluated in bladder cancer cells (n = 14) and paraffin-embedded primary bladder tumors (n = 61), using a methylation-specific multiplex ligation-dependent probe amplification assay (MS-MLPA). Recurrence, progression, and disease-specific survival were analyzed using univariate and multivariate Cox models. PRDM2, HLTF, ID4, DLC1, BNIP3, H2AFX, CACNA1G, TGIF, and CACNA1A were discovered methylated in bladder cancer. The methylation of RUNX3 (p = 0.026), TWIST1 (p = 0.009), SFRP4 (p = 0.002), and CCND2 (p = 0.027) correlated to tumor stage. Univariate analyses indicated prognostic associations for recurrence (DLC1, SFRP5, H2AFX, CACNA1G), progression (DLC1, SFRP5, CACNA1G), disease-specific (PRDM2, DLC1, SFRP5, CACNA1G, and TIMP3), and overall survival (SFRP5 and TIMP3). In multivariate analyses, several TSGs remained as independent prognosticators for recurrence (SFRP5, H2AFX), progression (CACNA1G), and disease-specific survival (SFRP5). Thus, a novel set of TSGs was identified, frequently methylated in bladder cancer cells and tumors. TSG methylation allowed histopathologic and outcome stratification using paraffin-embedded tumors. This is clinically relevant by offering a strategy for the management of patients affected with uroepithelial neoplasias in pathology routine laboratories.Keywords
This publication has 30 references indexed in Scilit:
- Methylation of a Novel Panel of Tumor Suppressor Genes in Urine Moves Forward Noninvasive Diagnosis and Prognosis of Bladder Cancer: A 2-Center Prospective StudyJournal of Urology, 2013
- Hypermethylation in bladder cancer: biological pathways and translational applicationsTumor Biology, 2012
- Identification and Validation of the Methylated TWIST1 and NID2 Genes through Real-Time Methylation-Specific Polymerase Chain Reaction Assays for the Noninvasive Detection of Primary Bladder Cancer in Urine SamplesEuropean Urology, 2010
- Methylation of the RUNX3 Promoter as a Potential Prognostic Marker for Bladder TumorJournal of Urology, 2008
- Tissue Inhibitor of Metalloproteinases-3 Promoter Methylation is an Independent Prognostic Factor for Bladder CancerJournal of Urology, 2008
- A Novel Set of DNA Methylation Markers in Urine Sediments for Sensitive/Specific Detection of Bladder CancerClinical Cancer Research, 2007
- Evidence for the early onset of aberrant promoter methylation in urothelial carcinomaThe Journal of Pathology, 2006
- Methylation Profiling of Urothelial Carcinoma in Bladder Biopsy and UrineActa Cytologica, 2006
- RUNX3 Inactivation by Point Mutations and Aberrant DNA Methylation in Bladder TumorsCancer Research, 2005
- Epigenetic Inactivation of SFRP Genes and TP53 Alteration Act Jointly as Markers of Invasive Bladder CancerCancer Research, 2005